HOME >> MEDICINE >> NEWS
European commission grants "orphan" status for new acute myeloid leukaemia treatment

Wyeth-Ayerst Pharmaceuticals, the pharmaceutical division of American Home Products Corporation (NYSE:AHP),announced today that the European Commission has designated Mylotarg(gemtuzumab ozogamicin)as an "orphan medicinal product." The Commission decision follows a positive opinion adopted on 13 September 2000 by the Committee on Orphan Medicinal Products (COMP) of the European Agency for the Evaluation of Medicinal Products (EMEA).

"We anticipate that Mylotarg will become an important treatment option for European patients aged 60 and over with CD33-positive relapsed acute myeloid leukaemia (AML)," says L. Patrick Gage, Ph.D., President, Wyeth-Ayerst Research. "Its mechanism of action focuses on using antibody-antigen specificity to target delivery of potent chemotherapy to myeloid leukaemic cells. This compound represents the first product from Wyeth's promising oncology pipeline."

As a designated orphan medicinal product, Mylotarg will have access to the Commission's "centralised" procedure for assessment of the marketing authorisation application. Orphan medicinal products are intended to treat patients with rare life-threatening or very serious diseases for which no satisfactory method of treatment exists or where the product will be of significant benefit.

Orphan medicinal products do not automatically qualify for approval under "exceptional circumstances," but companies that sponsor orphan products receive incentives for bringing these products to the market and to the patient. Such incentives include the possibility of protocol assistance from the EMEA and fee reductions for all types of centralised marketing authorisation evaluation activities. If approved by the EMEA, Mylotarg would be the first product available in Europe from a new class of anticancer therapy known as "antibody-targeted chemotherapy." Mylotarg utilizes a patented linker technology with a novel potent anti-tumor antibiotic, calicheamicin.

Mylotarg is being develo
'"/>

Contact: Roseann Ward
roseann.ward@ketchumcomms.co.uk
44-0-207-465-8752
Ketchum
14-Nov-2000


Page: 1 2 3

Related medicine news :

1. ESC releases the first European Guidelines on Percutaneous Coronary Interventions (PCI)
2. The European Society of Cardiology launches Women at Heart
3. Use of potentially inappropriate medications among elderly common in some European countries
4. European folic acid policies are not effective enough
5. New European cancer figures for 2004 major efforts needed against the big four killers
6. Third of European cancer patients use complementary and alternative therapies
7. A new service from the European Patent Office
8. European study highlights persistent 3 decade increase in childhood cancer incidence
9. European nations urged to ratify international treaty on tobacco control
10. Increased investment in radiotherapy will improve cure rates for European cancer patients
11. ESA looking for more European women to volunteer for WISE bed-rest study in Toulouse next year

Post Your Comments:
(Date:7/3/2015)... ... July 03, 2015 , ... ... providers, has been retained to lead a national president recruitment for ... in the healthcare industry, B. E. Smith has recently placed more than 1,000 ...
(Date:7/3/2015)... TX (PRWEB) , ... July 03, 2015 , ... Jennifer ... First Choice Emergency Room , the largest network of independent freestanding emergency rooms ... new facility medical director of our Sienna Plantation facility,” said Executive Medical Director of ...
(Date:7/3/2015)... ... 03, 2015 , ... The Celebrity Dresses is currently running a promotion through ... celebrities will have the opportunity to get 10% discount on orders that are over ... not have to use coupon codes or remember redemption codes. , There is ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... (D-Md.) for her introduction of the Stop Overdose Stat (S.O.S.) Act of 2015 ... Jack Reed (D-R.I.), this Act seeks to decrease drug overdose – especially of ...
(Date:7/2/2015)... ... ... “ LIFX ” was featured on NewsWatch as part of its monthly Tech Report, ... technology expert and special reporter for NewsWatch, conducted the review and shared with viewers ... , According to the U.S. Department of Energy, it’s very important to use energy-efficient ...
Breaking Medicine News(10 mins):Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3Health News:Celebrity Fashion Summer Party Dresses on sale at TheCelebrityDresses.com 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 3Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2
(Date:7/2/2015)... -- ResMed Inc. (NYSE: RMD ) today announced that ... June 30, 2015 results on Thursday, July 30, 2015, after ... with ResMed,s results will be issued after 1:00 p.m. US ... discuss operating results and future outlook. The earnings ... Time and the live webcast of the call can be ...
(Date:7/2/2015)... Roche,s Bloodhound technology is on the ... hematology testing, according to Kalorama Information.  The healthcare ... its Bloodhound digital cell imaging technology –as newly ... hematology analyzer – is notable as a play ... leader CellaVision, but also compete more broadly in ...
(Date:7/2/2015)... July 2, 2015  The Green Exchange, Inc., the ... first HIPAA compliant mobile app that connects cannabis growers ... medical marijuana, announced today that their service provides the ... Meadow and more than half a dozen other delivery ... Loud Cannabis is unique in that it connects ...
Breaking Medicine Technology:ResMed to Announce Fourth Quarter and Fiscal Year-End 2015 Results 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3New Cannabis Delivery App Gets Product to Patient in Under 7 Minutes 2
Cached News: